Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Comparative single-dose mRNA and ChAdOx1 vaccine effectiveness against SARS-CoV-2, including early variants of concern: a test-negative design, British Columbia, Canada

Danuta M Skowronski, Solmaz Setayeshgar, Macy Zou, Natalie Prystajecky, John R Tyson, Hind Sbihi, Chris D Fjell, Eleni Galanis, Monika Naus, David M Patrick, Shiraz El Adam, May Ahmed, Shinhye Kim, Bonnie Henry, Linda M N Hoang, Manish Sadarangani, Agatha N Jassem, Mel Krajden
doi: https://doi.org/10.1101/2021.09.20.21263875
Danuta M Skowronski
1BC Centre for Disease Control, Communicable Diseases and Immunization Services, Vancouver, British Columbia, Canada
2University of British Columbia, School of Population and Public Health, Vancouver, British Columbia, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: danuta.skowronski{at}bccdc.ca
Solmaz Setayeshgar
1BC Centre for Disease Control, Communicable Diseases and Immunization Services, Vancouver, British Columbia, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: solmaz.setayeshgar{at}bccdc.ca
Macy Zou
3BC Centre for Disease Control, Data and Analytics Services, Vancouver, British Columbia, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Natalie Prystajecky
4BC Centre for Disease Control, Public Health Laboratory, Vancouver, British Columbia, Canada
5University of British, Department of Pathology and Laboratory Medicine, Vancouver, British Columbia, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John R Tyson
4BC Centre for Disease Control, Public Health Laboratory, Vancouver, British Columbia, Canada
5University of British, Department of Pathology and Laboratory Medicine, Vancouver, British Columbia, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hind Sbihi
2University of British Columbia, School of Population and Public Health, Vancouver, British Columbia, Canada
3BC Centre for Disease Control, Data and Analytics Services, Vancouver, British Columbia, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chris D Fjell
4BC Centre for Disease Control, Public Health Laboratory, Vancouver, British Columbia, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eleni Galanis
1BC Centre for Disease Control, Communicable Diseases and Immunization Services, Vancouver, British Columbia, Canada
2University of British Columbia, School of Population and Public Health, Vancouver, British Columbia, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Monika Naus
1BC Centre for Disease Control, Communicable Diseases and Immunization Services, Vancouver, British Columbia, Canada
2University of British Columbia, School of Population and Public Health, Vancouver, British Columbia, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David M Patrick
1BC Centre for Disease Control, Communicable Diseases and Immunization Services, Vancouver, British Columbia, Canada
2University of British Columbia, School of Population and Public Health, Vancouver, British Columbia, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shiraz El Adam
1BC Centre for Disease Control, Communicable Diseases and Immunization Services, Vancouver, British Columbia, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
May Ahmed
1BC Centre for Disease Control, Communicable Diseases and Immunization Services, Vancouver, British Columbia, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shinhye Kim
1BC Centre for Disease Control, Communicable Diseases and Immunization Services, Vancouver, British Columbia, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bonnie Henry
2University of British Columbia, School of Population and Public Health, Vancouver, British Columbia, Canada
6Office of the Provincial Health Officer, Ministry of Health, Victoria, British Columbia, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linda M N Hoang
4BC Centre for Disease Control, Public Health Laboratory, Vancouver, British Columbia, Canada
5University of British, Department of Pathology and Laboratory Medicine, Vancouver, British Columbia, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Manish Sadarangani
7Vaccine Evaluation Center, BC Children’s Hospital Research Institute, Vancouver, British Columbia, Canada
8University of British Columbia, Department of Pediatrics, Vancouver, British Columbia, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Agatha N Jassem
4BC Centre for Disease Control, Public Health Laboratory, Vancouver, British Columbia, Canada
5University of British, Department of Pathology and Laboratory Medicine, Vancouver, British Columbia, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mel Krajden
4BC Centre for Disease Control, Public Health Laboratory, Vancouver, British Columbia, Canada
5University of British, Department of Pathology and Laboratory Medicine, Vancouver, British Columbia, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Introduction In randomized controlled trials, single-dose efficacy against SARS-CoV-2 illness exceeded 90% for mRNA vaccines (BNT162b2 and mRNA-1273), and 75% for ChAdOx1. In British Columbia (BC), Canada second doses were deferred up to 16 weeks and ChAdOx1 was only initially recommended for adults 55 years of age and older. We compared single-dose vaccine effectiveness (VE) during the spring 2021 wave in BC when Alpha and Gamma variants of concern (VOC) predominated.

Methods VE was estimated against infection and hospitalization by test-negative design: cases were RT-PCR test-positive for SARS-CoV-2 and controls were test-negative. Adults 50-69 years old with specimen collection between April 4 and May 22 (weeks 14-20) were included. Variant-specific VE was estimated between weeks 17-20 when genetic characterization of all case viruses was performed, primarily through whole genome sequencing.

Results VE analyses included 7,116 (10%) cases and 60,958 controls. Three-quarters of vaccinated participants received mRNA vaccine (60% BNT162b2, 15% mRNA-1273) and 25% received ChAdOx1. Half of genetically characterized viruses were Alpha, with 38% Gamma, 4% Delta and 8% non-VOCs. Single-dose VE against any infection was 75% (95%CI: 72-78) for BNT162b2, 82% (95%CI: 76-87) for mRNA-1273 and 61% (95%CI: 54-66) for ChAdOx1. VE against hospitalization was 83% (95%CI: 76-89), 85% (95%CI: 63-94) and 96% (95%CI: 86-99), respectively. VE against Alpha vs. Gamma infections did not differ among mRNA (78%;95%CI: 73-82 and 80%;95%CI: 74-85) or ChAdOx1 (66%;95%CI: 57-74 and 60%;95%CI: 48-69) recipients.

Conclusions A single dose of mRNA vaccine reduced the SARS-CoV-2 infection risk by at least 75%, including infections due to early VOC. Although effectiveness of a single dose of ChAdOx1 was lower at 60% against infection, just one dose of any vaccine reduced the hospitalization risk by more than 80%. In the context of constrained vaccine supplies, these findings have implications for global vaccine deployment to reduce the overall burden of infections and hospitalizations due to SARS-CoV-2.

Competing Interest Statement

DMS is Principal or co-Investigator on grants from the Michael Smith Foundation for Health Research, the Public Health Agency of Canada, and the Canadian Institutes of Health Research paid to her institution and unrelated to the current work. MK received grants/contracts paid to his institution from Roche, Hologic and Siemens, unrelated to this work. MS has been an investigator on projects, unrelated to the current work, funded by GlaxoSmithKline, Merck, Pfizer, Sanofi-Pasteur, Seqirus, Symvivo and VBI Vaccines. All funds have been paid to his institute, and he has not received any personal payments. Other authors have no conflicts of interest to disclose.

Clinical Trial

Not applicable

Funding Statement

No external funding was provided for this work.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Data linkages and analyses were authorized by the Provincial Health Officer under the Public Health Act and exempt from research ethics board review by the University of British Columbia Research Ethics Board.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Data sharing that complies with relevant legislation to protect privacy and confidentiality will be considered upon request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted September 22, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Comparative single-dose mRNA and ChAdOx1 vaccine effectiveness against SARS-CoV-2, including early variants of concern: a test-negative design, British Columbia, Canada
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Comparative single-dose mRNA and ChAdOx1 vaccine effectiveness against SARS-CoV-2, including early variants of concern: a test-negative design, British Columbia, Canada
Danuta M Skowronski, Solmaz Setayeshgar, Macy Zou, Natalie Prystajecky, John R Tyson, Hind Sbihi, Chris D Fjell, Eleni Galanis, Monika Naus, David M Patrick, Shiraz El Adam, May Ahmed, Shinhye Kim, Bonnie Henry, Linda M N Hoang, Manish Sadarangani, Agatha N Jassem, Mel Krajden
medRxiv 2021.09.20.21263875; doi: https://doi.org/10.1101/2021.09.20.21263875
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Comparative single-dose mRNA and ChAdOx1 vaccine effectiveness against SARS-CoV-2, including early variants of concern: a test-negative design, British Columbia, Canada
Danuta M Skowronski, Solmaz Setayeshgar, Macy Zou, Natalie Prystajecky, John R Tyson, Hind Sbihi, Chris D Fjell, Eleni Galanis, Monika Naus, David M Patrick, Shiraz El Adam, May Ahmed, Shinhye Kim, Bonnie Henry, Linda M N Hoang, Manish Sadarangani, Agatha N Jassem, Mel Krajden
medRxiv 2021.09.20.21263875; doi: https://doi.org/10.1101/2021.09.20.21263875

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (427)
  • Allergy and Immunology (753)
  • Anesthesia (220)
  • Cardiovascular Medicine (3281)
  • Dentistry and Oral Medicine (362)
  • Dermatology (274)
  • Emergency Medicine (478)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1164)
  • Epidemiology (13340)
  • Forensic Medicine (19)
  • Gastroenterology (897)
  • Genetic and Genomic Medicine (5130)
  • Geriatric Medicine (479)
  • Health Economics (781)
  • Health Informatics (3253)
  • Health Policy (1138)
  • Health Systems and Quality Improvement (1189)
  • Hematology (427)
  • HIV/AIDS (1014)
  • Infectious Diseases (except HIV/AIDS) (14613)
  • Intensive Care and Critical Care Medicine (910)
  • Medical Education (475)
  • Medical Ethics (126)
  • Nephrology (522)
  • Neurology (4901)
  • Nursing (261)
  • Nutrition (725)
  • Obstetrics and Gynecology (880)
  • Occupational and Environmental Health (795)
  • Oncology (2516)
  • Ophthalmology (722)
  • Orthopedics (280)
  • Otolaryngology (346)
  • Pain Medicine (323)
  • Palliative Medicine (90)
  • Pathology (540)
  • Pediatrics (1298)
  • Pharmacology and Therapeutics (548)
  • Primary Care Research (554)
  • Psychiatry and Clinical Psychology (4193)
  • Public and Global Health (7482)
  • Radiology and Imaging (1702)
  • Rehabilitation Medicine and Physical Therapy (1010)
  • Respiratory Medicine (979)
  • Rheumatology (478)
  • Sexual and Reproductive Health (495)
  • Sports Medicine (424)
  • Surgery (546)
  • Toxicology (71)
  • Transplantation (235)
  • Urology (203)